Gilead acquires biotechnology company Ouro for up to $2.2 billion
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
```htmlGolden Ten Data, March 24|Gilead Sciences announced that it has signed a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing therapies for autoimmune diseases. Gilead will pay a $1.675 billion upfront cash consideration (subject to customary adjustments), plus up to $500 million in potential milestone payments. This transaction adds OM336 (gamgertamig) to Gilead’s inflammation portfolio, a BCMAxCD3 T cell engager currently in clinical development. In ongoing phase 1/2 clinical studies, the drug has demonstrated efficacy in severe autoimmune diseases, including autoimmune hemolytic anemia and immune thrombocytopenia. OM336 has received Fast Track and Orphan Drug designations.```
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Stacks crypto jumps 13% – Could STX bulls extend the price rally?
AMBCrypto•2026/09/20 22:06
Tom Lee predicts the S&P 500 could surpass 8,200 points by the end of the year
AiCoin•2026/09/20 21:24

Michael Saylor, BlackRock, Metaplanet, and Strive purchase Bitcoin
AiCoin•2026/09/20 20:21
Crypto prices
MoreBitcoin
BTC
$81,137.27
-0.06%
Ethereum
ETH
$2,637.83
+0.36%
Tether USDt
USDT
$0.9998
+0.01%
BNB
BNB
$774.1
+1.74%
XRP
XRP
$1.41
-0.34%
USDC
USDC
$0.9999
+0.00%
Solana
SOL
$110.37
-0.14%
TRON
TRX
$0.3427
+0.80%
Zcash
ZEC
$1,513.89
+2.61%
Hyperliquid
HYPE
$93.5
+2.19%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now
